Versartis appoints Tracy Woody as CCO
Ms. Woody has had a successful career with over 20 years of experience in the pharmaceutical and biotech industries.
Most recently Ms. Woody served as the Chief Commercial Officer of KemPharm where she was responsible for building and managing the KemPharm commercial organization to support the company’s product pipeline.
Prior to that, she held the role of Vice President, Sales & Marketing for NextWave Pharmaceuticals, where she worked on the commercial preparation of the first once-daily, extended-release liquid methylphenidate drug in the U.S. to treat ADHD, now being marketed as Quillivant XR CII by Pfizer following its acquisition of NextWave.
Ms. Woody founded TMW Consulting, Inc., a provider of consulting services for emerging biotech and medical device companies.
As a consultant, she served as acting CEO for one of the firm’s clients, RetroJect, Inc., a private ophthalmic medical device company focused on the treatment of glaucoma.
Ms. Woody spent eight years at Greer Laboratories as part of the executive management team.
Earlier in her career, she was Director of Marketing for ALZA Corporation, and Marketing Manager in Pfizer’s U.S. Pharmaceuticals Group, where she helped lead the launches of Ditropan XL and Zoloft respectively.
Ms. Woody received a B.S. in Health Promotion and Applied Physiology from East Carolina University with a Minor in Business Administration. ■
LATEST MOVES FROM California
- CBRE Group appoints Beth F. Cobert to board
- Cloudera appoints two to board
- Verifone appoints Rowan Trollope to board of directors
- Catasys appoints Christopher Shirley as CFO
- Silicon Valley Bank promotes Michael Descheneaux to president
More inside POST
TUI group posts narrower loss in H1 Earnings
I'm stuck here. Why? Leadership